ArticleDiscover oncology2025
Causal relationships between cerebrospinal fluid metabolites, immune cell traits, and head and neck cancers.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
objectiveEmerging evidence suggests that cerebrospinal fluid (CSF) metabolites may serve as valuable biomarkers in head and neck cancers (HNCs). However, their causal relationships and potential mechanisms remain underexplored. We conducted a bidirectional Mendelian randomization (MR) study to evaluate causal relationships between genetically predicted CSF metabolites, immune cell traits (ICTs), and HNC risk.
methodsSummary-level data were obtained from large-scale genome-wide association studies (GWAS), including 388 CSF metabolites (n = 291), 731 ICTs (n = 3,757), and HNCs (n = 373,122). Bidirectional MR was employed to investigate causal associations, with mediation analysis applied to assess the potential mediating role of ICTs. A series of sensitivity analyses were conducted to address heterogeneity and pleiotropy concerns.
resultsForward MR identified nine CSF metabolites with causal associations: elevated citrulline and adenine correlated with reduced HNC risk, whereas hypoxanthine, N-acetylglutamate, N-acetylleucine, nicotinamide riboside, and X-24,813 conferred elevated risk. Dimethyl sulfone exhibited marginal protective effects. Reverse MR revealed tumor genetic susceptibility inversely modulated 12 metabolites, including pyroglutamine, 1-arachidonoyl-gpc (20:4n6), 3-hydroxy-2-ethylpropionate, 3-hydroxyoctanoate, 3-ureidopropionate, 7-methylguanine, adenine, guanosine, N2, and N2-dimethylguanosine, while elevating 2-aminophenol sulfate and N6-methyllysin. Mediation analyses suggested that CD45 on CD33br HLA DR + CD14dim and CD80 on granulocytes may potentially mediate the metabolite-HNC interactions.
conclusionThis study identifies bidirectional relationships between CSF metabolites and HNC risk and nominates ICTs as possible mediators. These findings implicate CSF metabolites in HNC pathogenesis and highlight their potential as diagnostic biomarkers and therapeutic targets, warranting experimental validation and clinical investigation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.